SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bianchine J, Stambler A, Harrison H 1971 Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser 7: 287294.
  • 2
    Imel EA, Econs MJ 2005 Fibroblast growth factor 23: Roles in health and disease. J Am Soc Nephrol 16: 25652575.
  • 3
    Econs MJ, McEnery PT 1997 Autosomal dominant hypophosphatemic rickets/osteomalacia: Clinical characterization of a novel renal phosphate wasting disorder. J Clin Endocrinol Metab 82: 674681.
  • 4
    ADHR_Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26: 345348.
  • 5
    White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ 2001 Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60: 20792086.
  • 6
    Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2002 Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143: 31793182.
  • 7
    Bai XY, Miao D, Goltzman D, Karaplis AC 2003 The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278: 98439849.
  • 8
    Ferrari SL, Bonjour J-P, Rizzoli R 2004 FGF-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90: 15191524.
  • 9
    Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB 2003 Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 22722279.
  • 10
    Burnett SM, Gunawardene S, Bringhyrst FR, Jeuppner H, Lee H, Finkelstein JS 2006 Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21: 11871196.
  • 11
    Antoniucci DM, Yamashita T, Portale AA 2006 Dietary phosphorus regulates serum FGF-23 concentrations in healthy men. J Clin Endocrinol Metab 91: 31443149.
  • 12
    Bai X, Miao D, Li J, Goltzman D, Karaplis AC 2004 Transgenic mice overexpressing human fibroblast growth factor 23(R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145: 52695279.
  • 13
    Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse H, Juppner H, Jonsson K 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the [alpha]1(I) collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis. Endocrinology 145: 30873094.
  • 14
    Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ 2006 Sensitivity of fibroblast growth factor 23 measurements in tumor induced osteomalacia. J Clin Endocrinol Metab 91: 20552061.
  • 15
    Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348: 16561663.
  • 16
    Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 49574960.
  • 17
    Walton RJ, Bijvoet OLM 1975 Nomogram for derivation of renal threshold phosphate concentration. Lancet 306: 309310.
  • 18
    Weber TJ, Liu S, Indridason OS, Quarles LD 2003 Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18: 12271234.
  • 19
    Costa T, Marie PJ, Scriver CR, Cole DE, Reade TM, Nogrady B, Glorieux FH, Delvin EE 1981 X-linked hypophosphatemia: Effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. J Clin Endocrinol Metab 52: 463472.
  • 20
    Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK 1985 Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest 75: 18581868.
  • 21
    Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N 2005 Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280: 25432549.
  • 22
    Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M, Miyamoto K 2005 Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288: E1101E1109.
  • 23
    Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD 2006 Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 13051315.